Seismic Therapeutic is a technology company.
Seismic Therapeutic has raised $220.0M across 2 funding rounds.
Seismic Therapeutic has raised $220.0M in total across 2 funding rounds.
Seismic Therapeutic has raised $220.0M in total across 2 funding rounds.
Seismic Therapeutic's investors include Andreessen Horowitz, Bessemer Venture Partners, Felicis Ventures, Firstminute Capital, Forerunner Ventures, Future Shape, Hoxton Ventures, Innovation Endeavors, Insight Partners, Left Lane Capital, Polaris Partners, Walden Catalyst Ventures.
Seismic Therapeutic is a biotechnology company founded in 2020 and headquartered in Cambridge, Massachusetts, that develops novel biologics for autoimmune diseases using its proprietary IMPACT platform, which integrates machine learning with structural biology, protein engineering, and translational immunology.[1][2][5] The platform addresses adaptive immune system dysregulation by accelerating biologics drug discovery, with an emerging pipeline including lead programs like S-1117, an engineered pan-IgG protease designed for chronic administration.[1][2] Serving patients with autoimmune conditions, Seismic solves the challenge of creating optimized therapies faster than traditional methods, backed by $222M in total funding (including a $121M recent round) and ~75 employees, generating $15.9M in revenue.[1][2]
The company targets immunology drug development, leveraging AI to overcome central hurdles in biologics creation, and has gained recognition as the Emerging Company of the Year in Life Sciences by the New England Venture Capital Association in 2022 for its innovative momentum.[2]
Seismic Therapeutic was founded in 2020 in Boston's biotech hub by a team including Jo Viney, PhD (Co-founder, President & CEO), with expertise in immunology, and other leaders like the Chief Technology Officer & SVP of Drug Creation.[1][2] The idea emerged from the need to integrate machine learning across biologics discovery—specifically structure, protein engineering, machine learning, and immunology—to tackle autoimmune diseases more effectively, as traditional approaches fell short in speed and precision.[2][3][5]
Early traction came swiftly: the company secured strong VC backing from investors like Bessemer Venture Partners, raised significant funding rounds totaling $222M, and demonstrated the IMPACT platform's capabilities by designing S-1117 and presenting data on its generalizability to other biologics modalities.[1][4] A pivotal moment was winning the 2022 NEVY Award for Emerging Company of the Year, highlighting its rapid rise in the New England ecosystem.[2]
Seismic rides the wave of AI-driven drug discovery in biotech, where machine learning is transforming slow, costly biologics development into faster, data-optimized processes amid rising autoimmune disease prevalence.[2][3][5] Timing is ideal in Boston's biotech cluster, fueled by VC syndicates and hubs like MassBio, positioning Seismic to capitalize on post-2020 funding booms and ML advancements in protein design.[1][2][4]
Market forces favoring it include surging demand for immunology therapies, regulatory tailwinds for AI tools, and investor appetite for high-impact startups—exemplified by its NEVY recognition and $222M funding.[1][2] Seismic influences the ecosystem by pioneering ML-immunology integration, inspiring similar VC-backed ventures and advancing the paradigm from empirical to predictive drug creation.[3][5]
Seismic Therapeutic is poised to advance its IMPACT-generated pipeline into clinical stages, with S-1117 and additional biologics targeting autoimmune markets projected to exceed $100B globally. Trends like generative AI for proteins and personalized immunology will amplify its edge, potentially leading to partnerships or acquisitions by big pharma seeking tech-enabled pipelines. As it evolves from emerging leader to pipeline powerhouse, Seismic could redefine biologics speed, delivering therapies that transform patient lives—echoing its founding vision of machine learning's seismic impact on immunology.[1][2][5]
Seismic Therapeutic has raised $220.0M across 2 funding rounds. Most recently, it raised $120.0M Series B in December 2023.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Dec 1, 2023 | $120.0M Series B | Andreessen Horowitz, Bessemer Venture Partners, Felicis Ventures, Firstminute Capital, Forerunner Ventures, Future Shape, Hoxton Ventures, Innovation Endeavors, Insight Partners, Left Lane Capital, Polaris Partners, Walden Catalyst Ventures, Anne Wojcicki | |
| Feb 1, 2022 | $100.0M Series A | Andreessen Horowitz, Felicis Ventures, Forerunner Ventures, Future Shape, Innovation Endeavors, Insight Partners, Left Lane Capital, Polaris Partners, Anne Wojcicki |